Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo

Lin,Jie; Wu,Yongji; Yang,Dajun; Zhao,Yongqiang

doi:10.3892/or.2013.2489

Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo

Authors:
- Jie Lin
- Yongji Wu
- Dajun Yang
- Yongqiang Zhao
View Affiliations

Affiliations: Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China, Ascenta Therapeutics, Inc., San Diego, CA, USA
Published online on: May 23, 2013 https://doi.org/10.3892/or.2013.2489
Pages: 731-738

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gossypol is a naturally occurring polyphenolic compound extracted from cotton plants. Recent studies revealed that gossypol is a non-peptidic small molecule inhibitor of Bcl-2/Bcl-xl. The aim of the present study was to investigate the induction of apoptosis and antitumor effects of gossypol acetate in multiple myeloma and the possible mechanism(s) of action. Our results showed that gossypol acetate resulted in a dose- and time-dependent inhibition of multiple myeloma cell proliferation, with an IC50 value to both U266 and Wus1 cells at 2.4, 2.2 µM at 48 h after treatment. Gossypol acetate effectively induced the apoptosis of multiple myeloma cells as demonstrated by typical morphological changes, DNA ladder formation and increase in the percentage of cells in subdiploid peak. Furthermore, colorimetric assays showed activation of both caspase-3 and caspase-9. Bcl-2 and Bcl-xl expression was decreased by 86.5±1.2% and 35.9±3.6%, respectively, after treatment with gossypol acetate at 25 µmol/l for 24 h. Preliminary studies in vivo showed that a growth inhibition (T/C) of 30.9% (gossypol acetate 40 mg/kg) was obtained in Balb/C mice bearing Wus1 cells. In addition, there was no body weight loss for the treated group in comparison with the vehicle mice. Our results demonstrated that the potent inhibitor of Bcl-2 and Bcl-xl gossypol acetate had significant antiproliferative and antiapoptotic effects on multiple myeloma cells in vitro and in vivo. Gossypol acetate may represent a promising new anticancer agent with a novel molecular mechanism and warrants further investigation as a single agent, or in combination with other chemotherapeutics, for human multiple myeloma with Bcl-2 overexpression.

View Figures

View References

1	Bird JM, Owen RG, D’Sa S, et al: Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 154:32–75. 2011. View Article : Google Scholar : PubMed/NCBI
2	Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
3	Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
4	Rajkumar SV, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 106:4050–4053. 2005. View Article : Google Scholar : PubMed/NCBI
5	Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
6	Richardson PG, Blood E, Mitsiades CS, et al: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 108:3458–3464. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kelekar A and Thompson CB: Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 8:324–330. 1998. View Article : Google Scholar : PubMed/NCBI
8	Pulley H and Mohammad R: Small-molecule inhibitors of Bcl-2 protein. Drugs Future. 29:369–381. 2004. View Article : Google Scholar
9	Reed JC: Bcl-2 family proteins. Oncogene. 17:3225–3236. 1998. View Article : Google Scholar
10	Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
11	Liu Q and Gazitt Y: Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood. 101:4105–4114. 2003. View Article : Google Scholar : PubMed/NCBI
12	Chang JS, Hsu YL, Kuo PL, Chiang LC and Lin CC: Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin Exp Pharmacol Physiol. 31:716–722. 2004. View Article : Google Scholar : PubMed/NCBI
13	Tuszynski GP and Cossu G: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res. 44:768–771. 1984.PubMed/NCBI
14	Zhang M, Liu H, Guo R, et al: Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol. 66:93–103. 2003. View Article : Google Scholar : PubMed/NCBI
15	Jaroszewski JW, Kaplan O and Cohen JS: Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies. Cancer Res. 50:6936–6943. 1990.PubMed/NCBI
16	Le Blanc M, Russo J, Kudelka AP and Smith JA: An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol Res. 46:551–555. 2002.PubMed/NCBI
17	Stein RC, Joseph AE, Matlin SA, Cunningham DC, et al: A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol. 30:480–482. 1992. View Article : Google Scholar : PubMed/NCBI
18	Enyedy IJ, Ling Y, Nacro K, et al: Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 44:4314–4324. 2001. View Article : Google Scholar : PubMed/NCBI
19	Kitada S, Leone M, Sareth S, et al: Discovery, characterization and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 46:4259–4264. 2003. View Article : Google Scholar
20	Yunis JJ, Frizzera G, Oken MM, et al: Multiple recurrent genomic defects in follicular lymphoma, a possible model for cancer. N Engl J Med. 316:79–84. 1987. View Article : Google Scholar : PubMed/NCBI
21	Pettersson M, Jernberg-Wiklund H, Larsson LG, et al: Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood. 79:495–502. 1992.PubMed/NCBI
22	Graninger WB, Seto M, Boutain B, Goldman P and Korsmeyer SJ: Expression of bcl-2 and bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest. 80:1512–1515. 1987. View Article : Google Scholar : PubMed/NCBI
23	Jernberg H, Zech L and Nilsson K: Cytogenetic studies on human myeloma cell lines. Int J Cancer. 40:811–817. 1987. View Article : Google Scholar : PubMed/NCBI
24	Peeters SD, Hovenga S, Rosati S and Vellenga E: Bcl-xl expression in multiple myeloma. Med Oncol. 22:183–190. 2005. View Article : Google Scholar : PubMed/NCBI
25	Linden M, Kirchhof N, Carlson C and Van Ness B: Targeted overexpression of Bcl-xl in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 103:2779–2786. 2004. View Article : Google Scholar : PubMed/NCBI
26	Xu L, Yang D, Wang S, et al: (−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther. 4:197–205. 2005.
27	Jiang J, Sugimoto Y, Liu S, et al: The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. Anticancer Res. 24:91–100. 2004.PubMed/NCBI
28	Band V, Hoffer AP, Band H, et al: Antiproliferative effect of gossypol and its optical isomers on human reproductive cancer cell lines. Gynecol Oncol. 32:273–277. 1989. View Article : Google Scholar : PubMed/NCBI
29	Coyle T, Levante S, Shetler M and Winfield J: In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neurooncol. 19:25–35. 1994. View Article : Google Scholar : PubMed/NCBI
30	Benz CC, Keniry MA, Ford JM, et al: Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol. 37:840–847. 1990.PubMed/NCBI
31	Shelley MD, Hartley L, Groundwater PW and Fish RG: Structure-activity studies on gossypol in tumor cell lines. Anticancer Drugs. 11:209–216. 2000. View Article : Google Scholar : PubMed/NCBI
32	Jarvis WD, Turner AJ, Povirk LF, Traylor RS and Grant S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukaemia cells by pharmacological inhibitors of protein kinase C. Cancer Res. 54:1707–1714. 1994.PubMed/NCBI
33	Blackstaffe L, Shelley MD and Fish RG: Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines. Melanoma Res. 7:364–372. 1997. View Article : Google Scholar : PubMed/NCBI
34	Mohammad RM, Wang S, Aboukameel A, et al: Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(−)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther. 4:13–21. 2005.
35	Ergun MA, Konac E, Erbas D and Ekmekci A: Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells. Cell Biol Int. 28:237–242. 2004. View Article : Google Scholar : PubMed/NCBI
36	Hou DX, Uto T, Tong X, et al: Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch Biochem Biophys. 428:179–187. 2004. View Article : Google Scholar : PubMed/NCBI
37	Bushunow P, Reidenberg MM, Wasenko J, et al: Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol. 43:79–86. 1999. View Article : Google Scholar : PubMed/NCBI
38	Flack MR, Pyle RG, Mullen NM, Lorenzo B, et al: Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab. 76:1019–1024. 1993.PubMed/NCBI
39	Van Poznak C, Seidman AD, Reidenberg MM, et al: Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat. 66:239–248. 2001.PubMed/NCBI
40	Oliver CL, Miranda MB, Shangary S, et al: (−)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther. 4:23–31. 2005.
41	Oliver CL, Bauer JA, Wolter KG, et al: In vitro effects of the BH3 mimetic, (−)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res. 10:7757–7763. 2004.